We are live on
!
Find out more
PM
Prosight Management Portfolio holdings
AUM
$610M
1-Year Est. Return
40.86%
This Fund
S&P 500
This Quarter
Est. Return
-1.07%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$203M
AUM Growth
+$1.2M
(+0.6%)
Cap. Flow
+$4.13M
Cap. Flow
% of AUM
2.04%
Top 10 Holdings %
Top 10 Hldgs %
50.42%
Holding
59
New
11
Increased
16
Reduced
17
Closed
14
Top Buys
| 1 |
Cue Biopharma
CUE
|
+$7.68M |
| 2 |
Aurinia Pharmaceuticals
AUPH
|
+$7.29M |
| 3 |
Baxter International
BAX
|
+$6.69M |
| 4 |
Prothena Corp
PRTA
|
+$6.56M |
| 5 |
MTCR
Metacrine, Inc. Common Stock
MTCR
|
+$5.31M |
Top Sells
| 1 |
Kura Oncology
KURA
|
+$12.8M |
| 2 |
Arrowhead Research
ARWR
|
+$4.93M |
| 3 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
+$4.28M |
| 4 |
Aldeyra Therapeutics
ALDX
|
+$3.41M |
| 5 |
Vericel Corp
VCEL
|
+$2.9M |
Sector Composition
| 1 | Healthcare | 92.16% |
| 2 | Technology | 4.47% |
| 3 | Energy | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ALXN
1
DELISTED
Alexion Pharmaceuticals
ALXN
| $13.3M | 6.54% |
115,800
+25,800
| +29% | +$2.78M |
|
|
ARNA
2
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $12.2M | 6.02% |
163,057
-64,155
| -28% | -$4.28M |
|
3
Bristol-Myers Squibb
BMY
$120B
| $11.2M | 5.52% |
185,500
+67,500
| +57% | +$4.06M |
|
|
RETA
4
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $11.2M | 5.51% |
114,554
+32,454
| +40% | +$4.06M |
|
|
5
Cue Biopharma
CUE
$122M
| $10.7M | 5.27% |
23,665
+13,322
| +129% | +$7.68M |
|
|
6
Baxter International
BAX
$11.5B
| $9.81M | 4.84% |
122,000
+79,500
| +187% | +$6.69M |
|
|
CHNG
7
DELISTED
Change Healthcare Inc. Common Stock
CHNG
| $9.06M | 4.47% |
624,200
-205,900
| -25% | -$2.62M |
|
|
8
Aurinia Pharmaceuticals
AUPH
$2.04B
| $8.76M | 4.33% |
595,000
+503,000
| +547% | +$7.29M |
|
|
9
Aldeyra Therapeutics
ALDX
$118M
| $8.09M | 3.99% |
1,092,000
-528,200
| -33% | -$3.41M |
|
10
Cigna
CI
$80.5B
| $7.96M | 3.93% |
47,000
+8,500
| +22% | +$1.5M |
|
11
Encompass Health
EHC
$10.9B
| $7.01M | 3.46% |
135,657
+94,302
| +228% | +$4.84M |
|
12
Centene
CNC
$33.1B
| $6.88M | 3.4% |
117,935
-41,765
| -26% | -$2.59M |
|
|
APTO
13
DELISTED
Aptose Biosciences, Inc.
APTO
| $6.83M | 3.37% |
2,531
+791
| +45% | +$1.97M |
|
14
Zimmer Biomet
ZBH
$17.7B
| $6.62M | 3.27% |
50,058
-20,497
| -29% | -$2.68M |
|
15
uniQure
QURE
$2.79B
| $6.31M | 3.12% |
171,429
+28,300
| +20% | +$1.16M |
|
|
16
Prothena Corp
PRTA
$447M
| $5.45M | 2.69% |
+545,195
| New | +$6.56M |
|
|
MTCR
17
DELISTED
Metacrine, Inc. Common Stock
MTCR
| $5.3M | 2.61% |
+518,796
| New | +$5.31M |
|
18
MeiraGTx Holdings
MGTX
$1.17B
| $5.18M | 2.56% |
391,099
-128,868
| -25% | -$1.7M |
|
19
AC Immune
ACIU
$242M
| $4.5M | 2.22% |
923,117
-253,684
| -22% | -$1.82M |
|
|
ALBO
20
DELISTED
Albireo Pharma Inc
ALBO
| $4.09M | 2.02% |
122,500
-76,300
| -38% | -$2.22M |
|
21
Iovance Biotherapeutics
IOVA
$1.88B
| $3.97M | 1.96% |
120,606
-94,394
| -44% | -$2.89M |
|
|
TBIO
22
DELISTED
Translate Bio, Inc. Common Stock
TBIO
| $3.84M | 1.89% |
282,100
+192,590
| +215% | +$2.97M |
|
|
CLLS
23
Cellectis
CLLS
$288M
| $3.43M | 1.69% |
185,180
-91,397
| -33% | -$1.62M |
|
|
24
Kura Oncology
KURA
$1B
| $3.29M | 1.62% |
107,367
-577,633
| -84% | -$12.8M |
|
|
ZGNX
25
DELISTED
Zogenix, Inc.
ZGNX
| $3.24M | 1.6% |
180,924
+34,578
| +24% | +$847K |
|
Similar funds
PL
BFC
ACM
FFWA
SAM
CBB
AIG
IA